NIOX MINO®, a hand-held device for the measurement of airway inflammation and monitoring of patients with asthma, has just been 510(k) cleared by the FDA. NIOX MINO, a product of Swedish company Aerocrine AB, is designed to measure fractional exhaled nitric oxide (FENO), an inflammatory marker. The company promotes its product as a device that will “cost efficiently improve management and care of patients with inflammatory disorders, such as asthma.” The monitor is sensitive enough to detect as low as 5 particles per billion of exhaled nitric oxide. Read more here.
At Arizona Asthma and Allergy Institute, we are now using this new technology to further evaluate and manage asthma.
